These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7298249)

  • 1. Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets.
    Graffner C; Lagerström PO; Lundborg PN; Rönn OF
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):414-9. PubMed ID: 7298249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration of disopyramide given as capsules and controlled release tablets.
    Arnman K; Graffner C; Rikner L; Ryden L; Voog L
    Eur J Clin Pharmacol; 1983; 24(2):199-203. PubMed ID: 6840167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
    Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
    Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfer from immediate-release disopyramide to controlled-release disopyramide.
    DiPersio DM; Chow MS
    Angiology; 1987 Feb; 38(2 Pt 2):188-91. PubMed ID: 3103493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic evaluation of standard and controlled-release disopyramide.
    Siddoway LA; Barbey JT; Roden DM; Woosley RL
    Angiology; 1987 Feb; 38(2 Pt 2):184-7. PubMed ID: 3103492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules.
    Walter K; Weiss G; Laicher A; Stanislaus F
    Arzneimittelforschung; 1995 Aug; 45(8):886-90. PubMed ID: 7575754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.
    Karim A; Kook C; Campion J; Doherty M
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
    Jounela AJ; Pentikäinen PJ; Oksanen K
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):276-82. PubMed ID: 7107076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral forms of the oxime HI-6: a study of pharmacokinetics and tolerance after administration to healthy volunteers.
    Jovanovic D; Maksimovic M; Joksovic D; Kovacevic V
    Vet Hum Toxicol; 1990 Oct; 32(5):419-21. PubMed ID: 2238436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
    Nauta IL; van de Calseyde J; Hertzberger DP
    Curr Med Res Opin; 1983; 8(8):582-93. PubMed ID: 6653136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disopyramide concentrations in saliva.
    Aitio ML; Virtanen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The relative bioavailability and pharmacokinetics of chloral hydrate and its metabolites].
    Zimmermann T; Wehling M; Schulz HU
    Arzneimittelforschung; 1998 Jan; 48(1):5-12. PubMed ID: 9522024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers].
    Li T; Pang Y; Wang Z; Jia Y; Cheng Q; Sun J
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):541-3. PubMed ID: 12910715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.